Fatty liver clues found in immune proteins?
NCT ID NCT02820285
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study examined immune semaphorin proteins in the liver and fat tissue of 148 obese patients with non-alcoholic fatty liver disease (NAFLD). Researchers aimed to understand how these proteins relate to inflammation and liver damage. The study did not test any treatment but may help identify future diagnostic markers or targets for therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this research could point toward new diagnostic markers or future treatments for fatty liver disease.
- What could go wrong
- This is an observational study, not a treatment trial. It only looks at tissue samples and does not test any therapy, so direct patient benefit is not expected.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-ALCOHOLIC FATTY LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Service d'Hépato-Gastroentérologie - Hôpital de l'Archet
Nice, 06003, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a scan replace the needle? ultrasound and MRI put to the test against liver biopsy for fatty liver disease
- Can fish oil shrink a fatty liver?
- Could donating blood help control diabetes and fatty liver?
- Could a diabetes drug reverse liver scarring?
- Blood test and AI could spot liver cancer early, saving lives
- New blood test may sharpen diagnosis of autoimmune liver disease